Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection

Acta Pharmacologica Sinica

Volumn 29, Issue 10, 2008, Pages 1253-1260

  Xiao, Xiu Mei ^a   Xiao, Yong Hong ^b  

^a PEKING UNIVERSITY THIRD HOSPITAL   (China)

^b PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Antofloxacin hydrochloride; AUC24h MIC; Murine thigh infection model; PK PD; Staphylococcus aureus

Indexed keywords

ANTOFLOXACIN HYDROCHLORIDE; CYCLOPHOSPHAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; FEMALE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYOSITIS; NEUTROPENIA; NONHUMAN; NONLINEAR REGRESSION ANALYSIS; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; THIGH;

ANIMALS; ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NEUTROPENIA; OFLOXACIN; STAPHYLOCOCCAL INFECTIONS; THIGH;

EID: 53749099212     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2008.00872.x     Document Type: Article

References (24)

1. Andes D, Craig WA. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 2002 46 : 1665 70.
2. Andes D, Craig WA. Pharmacodynamics of the new des-f(6)-qui-nolone garenoxacin in a murine thigh infection model. Antimicrob Agents Chemother 2003 47 : 3935 41.
3. Drusano GL, Johnson DE, Rosen M, Standiford HC. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993 37 : 483 90.
4. Andes D, Craig WA. In vivo activities of amoxicillin and amoxi-cillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998 42 : 2375 9.
5. Joly-Guillou ML, Wolff M, Pocidalo JJ, Walker F, Carbon C. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother 1997 41 : 345 51.
6. Onyeji CO, Bui KQ, Owens RC Jr., Nicolau DP, Quintiliani R, Nightingale CH. Comparative efficacies of levofloxacin and ciprofloxacin against Streptococcus pneumoniae in a mouse model of experimental septicaemia. Int J Antimicrob Agents 1999 12 : 107 14.
7. Xiao XM, Xiao YH. Establishment of a neutropenic-mouse thigh model with S aureus infection. Chin J Clin Pharmacol 2007 23 : 45 9.
8. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993 37 : 1073 81.
9. Lister PD, Sanders CC. Pharmacodynamics of levofloxacin and ciprofloxacin against Streptococcus pneumoniae. J Antimicrob Chemother 1999 43 : 79 86.
10. Lister PD, Sanders CC. Pharmacodynamics of trovafloxacin, ofloxa-cin, and ciprofloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model. Antimicrob Agents Chemother 1999 43 : 1118 23.
11. Andes DR, Craig WA. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis 1998 27 : 47 50.
12. Forrest A, Chodosh S, Amantea MA, Collins DA, Schentag JJ. Phar-macokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997 40 Suppl A : 45 57.
13. Blaser J, Stone BB, Groner MC, Zinner SH. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987 31 : 1054 60.
14. Drusano GL, Preston SL, Owens RC Jr., Ambrose PG. Fluoroquino-lone pharmacodynamics. Clin Infect Dis 2001 33 : 2091 6.
15. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998 26 : 1 10 quiz 11-2.
16. Dudley MN, Blaser J, Gilbert D, Mayer KH, Zinner SH. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis 1991 164 : 499 506.
17. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988 158 : 831 47.
18. Dudley MN. Pharmacodynamics and pharmacokinetics of antibiotics with special reference to the fluoroquinolones. Am J Med 1991 91 : 45S 50S.
19. He YC, He, YJ, Xu L, Lv YH, Liu HX, Sun RY, Zheng QS. Design of a clinical trial of non-inferiority for treating acute bacterial infections and its quantitative analysis. J Clin Pharmacol Ther 2007 11 : 1299 305.
20. Lv Y, Xiao YH, Liu Y, Xia YH Li TY Tolerance of antofloxacin hy-drochloride after ascending single oral dose administration in healthy male volunteers. Chin J Clin Pharmacol 2008 24 : 17 20.
21. Leggett JE, Ebert S, Fantin B, Craig WA. Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against Gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis Suppl 1990 74 : 179 84.
22. Quintiliani R, Owens RC, Grant EM. Clinical role of fluoroquinolones in patients with respiratory tract infections. Infect Dis Clin Prac 1999 8 (suppl 1) : S28 S41.
23. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dorn-seif B, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998 279 : 125 9.
24. Andes D, Craig WA. Pharmacodynamics of a new streptogramin, XRP 2868, in murine thigh and lung infection models. Antimicrob Agents Chemother 2006 50 : 243 9.